Biomarkers that currently effect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1 and KRAS

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages 1-26

  Korpanty, Grzegorz J ^a   Graham, Donna M ^a   Vincent, Mark D ^b   Leighl, Natasha B ^a  

^a PRINCESS MARGARET HOSPITAL   (Canada)

^b LONDON REGIONAL CANCER PROGRAM   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; ANAPLASTIC LYMPHOMA KINASE; ANTINEOPLASTIC AGENT; AP 26113; AZD 9291; CABOZANTINIB; CARBOPLATIN; CERITINIB; CISPLATIN; CO 1686; CRIZOTINIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FICLATUZUMAB; FORETINIB; GEFITINIB; K RAS PROTEIN; ONARTUZUMAB; PEMETREXED; PF 06463922; PROTEIN TYROSINE KINASE; RILOTUMUMAB; ROS 1 PROTEIN; SCATTER FACTOR RECEPTOR; SELUMETINIB; TIVANTINIB; TSR 011; UNCLASSIFIED DRUG; UNINDEXED DRUG; ECHINODERM MICROTUBULE ASSOCIATED PROTEIN LIKE 4; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHOLIPASE C; PROTEIN TYROSINE KINASE INHIBITOR; RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR; ROS 1; SCATTER FACTOR; TRAMETINIB; TUMOR MARKER;

ARTICLE; DRUG EFFICACY; DRUG RESPONSE; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIGNAL TRANSDUCTION; CANCER CHEMOTHERAPY; CELL DIFFERENTIATION; CELL INVASION; CELL MOTILITY; CELL PROLIFERATION; CELL SURVIVAL; FUSION GENE; LUNG ADENOCARCINOMA; META ANALYSIS (TOPIC); ONCOGENE H RAS; ONCOGENE N RAS; PREDICTIVE VALUE; SHORT SURVEY; SURVIVAL RATE;

EID: 84904607389     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00204     Document Type: Article

References (121)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2013. CA: a cancer journal for clinicians 2013 631:11-30. doi:10.3322/caac.21166.
2. Azzoli CG, Temin S, Aliff T, Baker S, Jr., Brahmer J, Johnson DH, et al. 2011 Focused Update of 2009 American Society of Clinical Oncology Clinical Practice Guideline Update on Chemotherapy for Stage IV Non-Small-Cell Lung Cancer. J Clin Oncol 2010 2928:3825-31. doi:10.1200/JCO.2010.34.2774.
3. Scagliotti GV, Parikh P, von Pawel J, Biesma B, Vansteenkiste J, Manegold C, et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer. J Clin Oncol 2008 2621:3543-51. doi:10.1200/JCO.2007.15.0375.
4. Mok TS. Personalized medicine in lung cancer: what we need to know. Nat Rev Clin Oncol 2011 811:661-8. doi:10.1038/nrclinonc.2011.126.
5. Keedy VL, Temin S, Somerfield MR, Beasley MB, Johnson DH, McShane LM, et al. American Society of Clinical Oncology provisional clinical opinion: epidermal growth factor receptor EGFR Mutation testing for patients with advanced non-small-cell lung cancer considering first-line EGFR tyrosine kinase inhibitor therapy. J Clin Oncol 2011 2915:2121-7. doi:10.1200/JCO.2010.31.8923.
6. Pirker R, Herth FJ, Kerr KM, Filipits M, Taron M, Gandara D, et al. Consensus for EGFR mutation testing in non-small cell lung cancer: results from a European workshop. J Thorac Oncol 2010 510:1706-13. doi:10.1097/JTO.0b013e3181f1c8de.
7. Gandara DR, Li T, Lara PN, Jr., Mack PC, Kelly K, Miyamoto S, et al. Algorithm for codevelopment of new drug-predictive biomarker combinations: accounting for inter- and intrapatient tumor heterogeneity. Clin Lung Cancer 2012 135:321-5. doi:10.1016/j.cllc.2012.05.004.
8. Haber DA, Gray NS, Baselga J. The evolving war on cancer. Cell 2011 1451:19-24. doi:10.1016/j.cell.2011.03.026.
9. Peters S, Adjei AA, Gridelli C, Reck M, Kerr K, Felip E. Metastatic non-smallcell lung cancer NSCLC: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2012 23 Suppl 7:vii56-64. doi:10.1093/annonc/mds226.
10. Bazley LA, Gullick WJ. The epidermal growth factor receptor family. Endocr Relat Cancer 2005 12 Suppl 1:S17-27. doi:10.1677/erc.1.01032.
11. Hsieh AC, Moasser MM. Targeting HER proteins in cancer therapy and the role of the non-target HER3. Br J Cancer 2007 974:453-7. doi:10.1038/sj.bjc.6603910.
12. Scagliotti GV, Selvaggi G, Novello S, Hirsch FR. The biology of epidermal growth factor receptor in lung cancer. Clin Cancer Res 2004 1012 Pt 2:4227s-32s. doi:10.1158/1078-0432.CCR-040007.
13. Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 2007 73:169-81. doi:10.1038/nrc2088
14. Mendelsohn J, Baselga J. Epidermal growth factor receptor targeting in cancer. Semin Oncol 2006 334:369-85. doi:10.1053/j.seminoncol.2006.04.003.
15. Gschwind A, Fischer OM, Ullrich A. The discovery of receptor tyrosine kinases: targets for cancer therapy. Nat Rev Cancer 2004 45:361-70. doi:10.1038/nrc1360.
16. Giaccone G. The role of gefitinib in lung cancer treatment. Clin Cancer Res 2004 1012 Pt 2:4233s-7s. doi:10.1158/1078-0432.CCR-040005.
17. Perez-Soler R. The role of erlotinib Tarceva, OSI 774 in the treatment of nonsmall cell lung cancer. Clin Cancer Res 2004 1012 Pt 2:4238s-40s. doi:10.1158/1078-0432.CCR-040017.
18. Miller VA, Kris MG, Shah N, Patel J, Azzoli C, Gomez J, et al. Bronchioloalveolar pathologic subtype and smoking history predict sensitivity to gefitinib in advanced non-small-cell lung cancer. J Clin Oncol 2004 226:1103- doi:10.1200/JCO.2004.08.158.
19. Pao W, Zakowski M, Cordon-Cardo C, Ben-Porat L, Kris MG, Miller VA. Molecular characteristics of non-small cell lung cancer NSCLC patients sensitive to gefitinib. ASCO Meeting Abstracts 2004 2214_suppl:7025.
20. Kris MG, Sandler A, Miller V, Cespon M, Zakowski M, Pizzo B, et al. Cigarette smoking history predicts sensitivity to erlotinib: Results of a phase II trial in patients with bronchioloalveolar carcinoma BAC. ASCO Meeting Abstracts 2004 2214_suppl:7062.
21. Fukuoka M, Yano S, Giaccone G, Tamura T, Nakagawa K, Douillard JY, et al. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer The IDEAL 1 Trial [corrected]. J Clin Oncol 2003 2112:2237-46. doi:10.1200/JCO.2003.10.038.
22. Kris MG, Natale RB, Herbst RS, Lynch TJ, Jr., Prager D, Belani CP, et al. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. Jama 2003 29016:2149-58. doi:10.1001/jama.290.16.2149.
23. Shigematsu H, Lin L, Takahashi T, Nomura M, Suzuki M, Wistuba, II, et al. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 2005 975:339-46. doi:10.1093/jnci/dji055.
24. Perez-Soler R. Phase II clinical trial data with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib OSI-774 in non-small-cell lung cancer. Clin Lung Cancer 2004 6 Suppl 1:S20-3. doi:10.3816/CLC.2004.s.010.
25. Shepherd FA, Rodrigues Pereira J, Ciuleanu T, Tan EH, Hirsh V, Thongprasert S, et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 2005 3532:123-32. doi:10.1056/NEJMoa050753.
26. Thatcher N, Chang A, Parikh P, Rodrigues Pereira J, Ciuleanu T, von Pawel J, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study Iressa Survival Evaluation in Lung Cancer. Lancet 2005 3669496:1527-37. doi:0.1016/S0140-67360567625-8.
27. Herbst RS, Prager D, Hermann R, Fehrenbacher L, Johnson BE, Sandler A, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride OSI-774 combined withcarboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005 2325:5892-9. doi:10.1200/JCO.2005.02.840.
28. Lee DH, Han JY, Lee HG, Lee JJ, Lee EK, Kim HY, et al. Gefitinib as a first-line therapy of advanced or metastatic adenocarcinoma of the lung in never-smokers. Clin Cancer Res 2005 118:3032-7. doi:0.1158/1078-0432.CCR-04-2149.
29. Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 2004 35021:2129-39. doi:10.1056/NEJMoa040938.
30. Paez JG, Janne PA, Lee JC, Tracy S, Greulich H, Gabriel S, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 2004 3045676:1497-500. doi:10.1126/science.1099314.
31. Pao W, Miller V, Zakowski M, Doherty J, Politi K, Sarkaria I, et al. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A 2004 10136:13306-11. doi:10.1073/pnas.0405220101.
32. Kosaka T, Yatabe Y, Endoh H, Kuwano H, Takahashi T, Mitsudomi T. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 2004 6424:8919-23. doi:10.1158/0008-5472.CAN-04-2818.
33. Carey KD, Garton AJ, Romero MS, Kahler J, Thomson S, Ross S, et al. Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res 2006 6616:8163-71. doi:10.1158/0008-5472.CAN-06-0453.
34. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med 2009 36110:947-57. doi:10.1056/NEJMoa0810699.
35. Janne PA, Wang X, Socinski MA, Crawford J, Stinchcombe TE, Gu L, et al. Randomized Phase II Trial of Erlotinib Alone or With Carboplatin and Paclitaxel in Patients Who Were Never or Light Former Smokers With Advanced Lung Adenocarcinoma: CALGB 30406 Trial. J Clin Oncol 2012 3017:2063-9. doi:0.1200/JCO.2011.40.1315.
36. Han JY, Park K, Kim SW, Lee DH, Kim HY, Kim HT, et al. First-SIGNAL: firstline single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. J Clin Oncol 2012 3010:1122-8. doi:10.1200/JCO.2011.36.8456.
37. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Tsurutani J, et al. Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor WJTOG3405: an open label, randomised phase 3 trial. Lancet Oncol 2010 112:121-8. doi:10.1016/S1470-20450970364-X.
38. Mitsudomi T, Morita S, Yatabe Y, Negoro S, Okamoto I, Seto T, et al. Updated overall survival results of WJTOG 3405, a randomized phase III trial comparing gefitinib G with cisplatin plus docetaxel CD as the first-line treatment for patients with non-small cell lung cancer harboring mutations of the epidermalgrowth factor receptor EGFR. ASCO Meeting Abstracts 2012 3015_suppl:7521.
39. Maemondo M, Inoue A, Kobayashi K, Sugawara S, Oizumi S, Isobe H, et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR. N Engl J Med 2010 36225:2380-8. doi:10.1056/NEJMoa0909530.
40. Inoue A, Kobayashi K, Maemondo M, Sugawara S, Oizumi S, Isobe H, et al. Final overall survival results of NEJ002, a phase III trial comparing gefitinib to carboplatin CBDCA plus paclitaxel TXL as the first-line treatment for advanced non-small cell lung cancer NSCLC with EGFR mutations. ASCO Meeting Abstracts 2011 2915_suppl:7519.
41. Zhou C, Wu YL, Chen G, Feng J, Liu XQ, Wang C, et al. Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutationpositive non-small-cell lung cancer OPTIMAL, CTONG-0802: a multicentre, open-label, randomised, phase 3 study. Lancet Oncol 2011 128:735-42. doi:10.1016/S1470-20451170184-X.
42. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer EURTAC: a multicentre, open-label, randomised phase 3 trial. Lancet Oncol 2012 133:239-46. doi:10.1016/S1470-20451170393-X.
43. Rosell R, Gervais R, Vergnenegre A, Massuti B, Felip E, Cardenal F, et al. Erlotinib versus chemotherapy CT in advanced non-small cell lung cancer NSCLC patients p with epidermal growth factor receptor EGFR mutations: Interim results of the European Erlotinib Versus Chemotherapy EURTAC phase III randomized trial. ASCO Meeting Abstracts 2011 2915_suppl:7503.
44. Sequist LV, Martins RG, Spigel D, Grunberg SM, Spira A, Janne PA, et al. Firstline gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 2008 2615:2442-9. doi:10.1200/JCO.2007.14.8494.
45. Inoue A, Suzuki T, Fukuhara T, Maemondo M, Kimura Y, Morikawa N, et al. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 2006 2421:3340-6. doi:10.1200/JCO.2005.05.4692.
46. Asahina H, Yamazaki K, Kinoshita I, Sukoh N, Harada M, Yokouchi H, et al. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 2006 958:998-1004. doi:10.1038/sj.bjc.6603393.
47. Minkovsky N, Berezov A. BIBW-2992, a dual receptor tyrosine kinase inhibitor for the treatment of solid tumors. Curr Opin Investig Drugs 2008 912:1336-46.
48. Li D, Ambrogio L, Shimamura T, Kubo S, Takahashi M, Chirieac LR, et al. BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models. Oncogene 2008 2734:4702-11. doi:10.1038/onc.2008.109.
49. Yang JC-H, Schuler MH, Yamamoto N, O'Byrne KJ, Hirsh V, Mok T, et al. LUX-Lung 3: A randomized, open-label, phase III study of afatinib versuspemetrexed and cisplatin as first-line treatment for patients with advanced adenocarcinoma of the lung harboring EGFR-activating mutations. ASCO Meeting Abstracts 2012 3018_suppl:LBA7500.
50. Yang JC-H, Sequist LV, Schuler MH, Mok T, Yamamoto N, O'Byrne KJ, et al. Overall survival OS in patients pts with advanced non-small cell lung cancer NSCLC harboring common Del19/L858R epidermal growth factor receptor mutations EGFR mut: Pooled analysis of two large open-label phase III studies LUX-Lung 3 [LL3] and LUX-Lung 6 [LL6] comparing afatinib with chemotherapy CT. ASCO Meeting Abstracts 2014 3215_suppl:8004.
51. Godin-Heymann N, Ulkus L, Brannigan BW, McDermott U, Lamb J, Maheswaran S, et al. The T790M gatekeeper mutation in EGFR mediates resistance to low concentrations of an irreversible EGFR inhibitor. Mol Cancer Ther 2008 74:874-9. doi:10.1158/1535-7163.MCT-07-2387.
52. Janne PA, Ramalingam SS, Yang JC-H, Ahn M-J, Kim D-W, Kim S-W, et al. Clinical activity of the mutant-selective EGFR inhibitor AZD9291 in patients pts with EGFR inhibitor-resistant non-small cell lung cancer NSCLC. ASCO Meeting Abstracts 2014 3215_suppl:8009.
53. Sequist LV, Soria J-C, Gadgeel SM, Wakelee HA, Camidge DR, Varga A, et al. First-in-human evaluation of CO-1686, an irreversible, highly selective tyrosine kinase inhibitor of mutations of EGFR activating and T790M. ASCO Meeting Abstracts 2014 3215_suppl:8010.
54. Soda M, Choi YL, Enomoto M, Takada S, Yamashita Y, Ishikawa S, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature 2007 4487153:561-6. doi:10.1038/nature05945.
55. Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010 36318:1693-703. doi:10.1056/NEJMoa1006448.
56. Horn L, Pao W. EML4-ALK: honing in on a new target in non-small-cell lung cancer. J Clin Oncol 2009 2726:4232-5. doi:10.1200/JCO.2009.23.6661.
57. Shaw AT, Yeap BY, Mino-Kenudson M, Digumarthy SR, Costa DB, Heist RS, et al. Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK. J Clin Oncol 2009 2726:4247-53. doi:10.1200/JCO.2009.22.6993.
58. Inamura K, Takeuchi K, Togashi Y, Hatano S, Ninomiya H, Motoi N, et al. EML4-ALK lung cancers are characterized by rare other mutations, a TTF-1 cell lineage, an acinar histology, and young onset. Mod Pathol 2009 224:508-15. doi:10.1038/modpathol.2009.2.
59. Camidge DR, Kono SA, Flacco A, Tan AC, Doebele RC, Zhou Q, et al. Optimizing the detection of lung cancer patients harboring anaplastic lymphoma kinase ALK gene rearrangements potentially suitable for ALK inhibitor treatment. Clin Cancer Res 2010 1622:5581-90. doi:10.1158/1078-0432.CCR-10-0851.
60. Rikova K, Guo A, Zeng Q, Possemato A, Yu J, Haack H, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell 2007 1316:1190-203. doi:10.1016/j.cell.2007.11.025.
61. Camidge DR, Bang YJ, Kwak EL, Iafrate AJ, Varella-Garcia M, Fox SB, et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study. Lancet Oncol 2012 1310:1011-9. doi:10.1016/S1470-20451270344-3.
62. Ou SH, Bazhenova L, Camidge DR, Solomon BJ, Herman J, Kain T, et al. Rapid and dramatic radiographic and clinical response to an ALK inhibitor crizotinib, PF02341066 in an ALK translocation-positive patient with non-small cell lung cancer. J Thorac Oncol 2010 512:2044-6. doi:10.1097/JTO.0b013e318200f9ff.
63. Ou SH, Kwak EL, Siwak-Tapp C, Dy J, Bergethon K, Clark JW, et al. Activity of crizotinib PF02341066, a dual mesenchymal-epithelial transition MET and anaplastic lymphoma kinase ALK inhibitor, in a non-small cell lung cancer patient with de novo MET amplification. J Thorac Oncol 2011 65:942-6.
64. Shaw AT, Yeap BY, Solomon BJ, Riely GJ, Gainor J, Engelman JA, et al. Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis. Lancet Oncol 2011 1211:1004-12. doi:10.1016/S1470-20451170232-7.
65. Kim D-W, Ahn M-J, Shi Y, De Pas TM, Yang P-C, Riely GJ, et al. Results of a global phase II study with crizotinib in advanced ALK-positive non-small cell lung cancer NSCLC. ASCO Meeting Abstracts 2011 3015_suppl:7533.
66. Crino L, Kim D, Riely GJ, Janne PA, Blackhall FH, Camidge DR, et al. Initial phase II results with crizotinib in advanced ALK-positive non-small cell lung cancer NSCLC: PROFILE 1005. ASCO Meeting Abstracts 2011 2915_suppl:7514.
67. Mok T, Kim D-W, Wu Y-L, Solomon BJ, Nakagawa K, Mekhail T, et al. Firstline crizotinib versus pemetrexed-cisplatin or pemetrexed-carboplatin in patients pts with advanced ALK-positive non-squamous non-small cell lung cancer NSCLC: results of a phase III study PROFILE 1014. ASCO Meeting Abstracts 2014 3215_suppl:8002.
68. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med 2013 36825:2385-94.
69. Camidge DR, Bazhenova L, Salgia R, Weiss GJ, Langer CJ, Shaw AT, et al. First-in-human dose-finding study of the ALK/EGFR inhibitor AP26113 in patients with advanced malignancies: Updated results. ASCO Meeting Abstracts 2013 3115_suppl:8031.
70. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med 2014 37013:1189-97.
71. Ma PC, Maulik G, Christensen J, Salgia R. c-Met: structure, functions and potential for therapeutic inhibition. Cancer Metastasis Rev 2003 224:309-25.
72. Cipriani NA, Abidoye OO, Vokes E, Salgia R. MET as a target for treatment of chest tumors. Lung Cancer 2009 632:169-79. doi:10.1016/j.lungcan.2008.06.011.
73. Sadiq AA, Geynisman DM, Salgia R. Inhibition of MET receptor tyrosine kinase and its ligand hepatocyte growth factor. J Thorac Oncol 2011 611 Suppl 4:S1810-1. doi:10.1097/01.JTO.0000407568.45147.43.
74. Park S, Choi YL, Sung CO, An J, Seo J, Ahn MJ, et al. High MET copy number and MET overexpression: poor outcome in non-small cell lung cancer patients. Histol Histopathol 2012 272:197-207.
75. Cappuzzo F, Marchetti A, Skokan M, Rossi E, Gajapathy S, Felicioni L, et al. Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients. J Clin Oncol 2009 2710:1667-74. doi:10.1200/JCO.2008.19.1635.
76. Engelman JA, Zejnullahu K, Mitsudomi T, Song Y, Hyland C, Park JO, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007 3165827:1039-43. doi:10.1126/science.1141478.
77. Xu L, Kikuchi E, Xu C, Ebi H, Ercan D, Cheng KA, et al. Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res 2012 7213:3302- doi:10.1158/0008-5472.CAN-11-3720.
78. Robinson KW, Sandler AB. The role of MET receptor tyrosine kinase in nonsmall cell lung cancer and clinical development of targeted anti-MET agents. Oncologist 2013 182:115-22. doi:10.1634/theoncologist.2012-0262.
79. Sadiq AA, Salgia R. MET as a possible target for non-small-cell lung cancer. J Clin Oncol 2013 318:1089-96. doi:10.1200/JCO.2012.43.9422.
80. Spigel DR, Ervin TJ, Ramlau R, Daniel DB, Goldschmidt JH, Blumenschein GR, et al. Final efficacy results from OAM4558g, a randomized phase II study evaluating MetMAb or placebo in combination with erlotinib in advanced NSCLC. ASCO Meeting Abstracts 2011 2915_suppl:7505.
81. Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, et al. Onartuzumab plus erlotinib versus erlotinib in previously treated stage IIIb or IV NSCLC: Results from the pivotal phase III randomized, multicenter, placebocontrolled METLung OAM4971g global trial. ASCO Meeting Abstracts 2014 3215_suppl:8000.
82. Sequist LV, von Pawel J, Garmey EG, Akerley WL, Brugger W, Ferrari D, et al. Randomized phase II study of erlotinib plus tivantinib versus erlotinib plus placebo in previously treated non-small-cell lung cancer. J Clin Oncol 2011 2924:3307-15. doi:10.1200/JCO.2010.34.0570.
83. Munshi N, Jeay S, Li Y, Chen CR, France DS, Ashwell MA, et al. ARQ 197, a novel and selective inhibitor of the human c-Met receptor tyrosine kinase with antitumor activity. Mol Cancer Ther 2010 96:1544-53. doi:10.1158/1535-7163.MCT-09-1173.
84. Scagliotti GV, Novello S, Schiller JH, Hirsh V, Sequist LV, Soria JC, et al. Rationale and design of MARQUEE: a phase III, randomized, double-blind study of tivantinib plus erlotinib versus placebo plus erlotinib in previously treated patients with locally advanced or metastatic, nonsquamous, non-small-cell lung cancer. Clin Lung Cancer 2012 135:391-5. doi:10.1016/j.cllc.2012.01.003.
85. Camidge DR, Ou S-HI, Shapiro G, Otterson GA, Villaruz LC, Villalona-Calero MA, et al. Efficacy and safety of crizotinib in patients with advanced c-METamplified non-small cell lung cancer NSCLC. ASCO Meeting Abstracts 2014 3215_suppl:8001.
86. Acquaviva J, Wong R, Charest A. The multifaceted roles of the receptor tyrosine kinase ROS in development and cancer. Biochim Biophys Acta 2009 17951:37-52. doi:10.1016/j.bbcan.2008.07.006.
87. Birchmeier C, Sharma S, Wigler M. Expression and rearrangement of the ROS1 gene in human glioblastoma cells. Proc Natl Acad Sci U S A 1987 8424:9270- doi:10.1073/pnas.84.24.9270.
88. Gu TL, Deng X, Huang F, Tucker M, Crosby K, Rimkunas V, et al. Survey of tyrosine kinase signaling reveals ROS kinase fusions in human cholangiocarcinoma. PLoS One 2011 61:e15640. doi:10.1371/journal.pone.0015640.
89. Birch AH, Arcand SL, Oros KK, Rahimi K, Watters AK, Provencher D, et al. Chromosome 3 anomalies investigated by genome wide SNP analysis of benign, low malignant potential and low grade ovarian serous tumours. PLoS One 2011 612:e28250. doi:10.1371/journal.pone.0028250.
90. Bergethon K, Shaw AT, Ou SH, Katayama R, Lovly CM, McDonald NT, et al. ROS1 rearrangements define a unique molecular class of lung cancers. J Clin Oncol 2012 308:863-70. doi:10.1200/JCO.2011.35.6345.
91. Kim HR, Lim SM, Kim HJ, Hwang SK, Park JK, Shin E, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Annals of Oncology 2012 249:2364-70. doi:10.1093/annonc/mdt220.
92. Yoshida A, Kohno T, Tsuta K, Wakai S, Arai Y, Shimada Y, et al. ROS1-rearranged lung cancer: a clinicopathologic and molecular study of 15 surgical cases. Am J Surg Pathol 2013 374:554-62. doi:10.1097/PAS.0b013e3182758fe6.
93. Go H, Kim DW, Kim D, Keam B, Kim TM, Lee SH, et al. Clinicopathologic analysis of ROS1-rearranged non-small-cell lung cancer and proposal of a diagnostic algorithm. J Thorac Oncol 2013 811:1445-50. doi:10.1097/JTO.0b013e3182a4dd6e.
94. Shaw AT, Camidge DR, Engelman JA, Solomon BJ, Kwak EL, Clark JW, et al. Clinical activity of crizotinib in advanced non-small cell lung cancer NSCLC harboring ROS1 gene rearrangement. ASCO Meeting Abstracts 2012 3015_suppl:7508.
95. Mescam-Mancini L, Lantuejoul S, Moro-Sibilot D, Rouquette I, Souquet PJ, Audigier-Valette C, et al. On the relevance of a testing algorithm for the detection of ROS1-rearranged lung adenocarcinomas. Lung Cancer 2014 832:168-73. doi:10.1016/j.lungcan.2013.11.019.
96. Rodenhuis S, Slebos RJ. The ras oncogenes in human lung cancer. Am Rev Respir Dis 1990 1426 Pt 2:S27-30.
97. Rodenhuis S. ras and human tumors. Semin Cancer Biol 1992 34:241-7.
98. Harvey JJ. An Unidentified Virus Which Causes the Rapid Production of Tumours in Mice. Nature 1964 204:1104-5. doi:10.1038/2041104b0.
99. Roberts PJ, Der CJ. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer. Oncogene 2007 2622:3291-310. doi:10.1038/sj.onc.1210422.
100. Karnoub AE, Weinberg RA. Ras oncogenes: split personalities. Nat Rev Mol Cell Biol 2008 97:517-31. doi:10.1038/nrm2438.
101. Slebos RJ, Kibbelaar RE, Dalesio O, Kooistra A, Stam J, Meijer CJ, et al. K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung. N Engl J Med 1990 3239:561-5.
102. Riely GJ, Kris MG, Rosenbaum D, Marks J, Li A, Chitale DA, et al. Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma. Clin Cancer Res 2008 1418:5731-4. doi:10.1158/1078-0432.CCR-08-0646.
103. Prior IA, Lewis PD, Mattos C. A comprehensive survey of Ras mutations in cancer. Cancer Res 2012 7210:2457-67. doi:10.1158/0008-5472.CAN-11-2612.
104. Schmid K, Oehl N, Wrba F, Pirker R, Pirker C, Filipits M. EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res 2009 1514:4554-60. doi:10.1158/1078-0432.CCR-09-0089.
105. Wang L, Hu H, Pan Y, Wang R, Li Y, Shen L, et al. PIK3CA mutations frequently coexist with EGFR/KRAS mutations in non-small cell lung cancer and suggest poor prognosis in EGFR/KRAS wildtype subgroup. PLoS One 2014 92:e88291. doi:10.1371/journal.pone.0088291.
106. Eberhard DA, Johnson BE, Amler LC, Goddard AD, Heldens SL, Herbst RS, et al. Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib. J Clin Oncol 2005 2325:5900-9. doi:10.1200/JCO.2005.02.857.
107. Rodenhuis S, van de Wetering ML, Mooi WJ, Evers SG, van Zandwijk N, Bos JL. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 1987 31715:929-35.
108. Mascaux C, Iannino N, Martin B, Paesmans M, Berghmans T, Dusart M, et al. The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis. Br J Cancer 2005 921:131-9. doi:10.1038/sj.bjc.6602258.
109. Shepherd FA, Domerg C, Hainaut P, Janne PA, Pignon JP, Graziano S, et al. Pooled analysis of the prognostic and predictive effects of KRAS mutation status and KRAS mutation subtype in early-stage resected non-small-cell lung cancer in four trials of adjuvant chemotherapy. J Clin Oncol 2013 3117:2173-81. doi:10.1200/JCO.2012.48.1390.
110. Martin P, Leighl NB, Tsao MS, Shepherd FA. KRAS mutations as prognostic and predictive markers in non-small cell lung cancer. J Thorac Oncol 2013 85:530-42. doi:10.1097/JTO.0b013e318283d958.
111. Raponi M, Winkler H, Dracopoli NC. KRAS mutations predict response to EGFR inhibitors. Curr Opin Pharmacol 2008 84:413-8. doi:10.1016/j.coph.2008.06.006.
112. Ahearn IM, Haigis K, Bar-Sagi D, Philips MR. Regulating the regulator: posttranslational modification of RAS. Nat Rev Mol Cell Biol 2011 131:39-51. doi:10.1038/nrm3255.
113. Hoshino R, Chatani Y, Yamori T, Tsuruo T, Oka H, Yoshida O, et al. Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 1999 183:813-22. doi:10.1038/sj.onc.1202367.
114. Janne PA, Shaw AT, Pereira JR, Jeannin G, Vansteenkiste J, Barrios C, et al. Selumetinib plus docetaxel for KRAS-mutant advanced non-small-cell lung cancer: a randomised, multicentre, placebo-controlled, phase 2 study. Lancet Oncol 2013 141:38-47. doi:10.1016/S1470-20451270489-8.
115. Kelly K, Mazieres J, Leighl NB, Barlesi F, Zalcman G, Gordon MS, et al. Oral MEK1/MEK2 inhibitor trametinib GSK1120212 in combination with pemetrexed for KRAS-mutant and wild-type WT advanced non-small cell lung cancer NSCLC: A phase I/Ib trial. ASCO Meeting Abstracts 2013 3115_suppl:8027.
116. Hanna N, Shepherd FA, Fossella FV, Pereira JR, De Marinis F, von Pawel J, et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with nonsmall-cell lung cancer previously treated with chemotherapy. J Clin Oncol 2004 229:1589-97. doi:10.1200/JCO.2004.08.163.
117. Riely GJ, Brahmer JR, Planchard D, Crino L, Doebele RC, Mas Lopez LA, et al. A randomized discontinuation phase II trial of ridaforolimus in non-small cell lung cancer NSCLC patients with KRAS mutations. ASCO Meeting Abstracts 2012 3015_suppl:7531.
118. Roberts PJ, Stinchcombe TE. KRAS mutation: should we test for it, and does it matter? J Clin Oncol 2013 318:1112-21. doi:10.1200/JCO.2012.43.0454.
119. Langer CJ, Besse B, Gualberto A, Brambilla E, Soria JC. The evolving role of histology in the management of advanced non-small-cell lung cancer. J Clin Oncol 2010 2836:5311-20. doi:10.1200/JCO.2010.28.8126.
120. Pao W, Girard N. New driver mutations in non-small-cell lung cancer. Lancet Oncol 2011 122:175-80. doi:10.1016/S1470-20451070087-5.
121. Bettegowda C, Sausen M, Leary RJ, Kinde I, Wang Y, Agrawal N, et al. Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med 2014 6224:224ra24. doi:10.1126/scitranslmed.3007094.